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Abstract
Objective
To assess the efficacy and safety of transdermal rivastigmine for the treatment of HIV-asso-
ciated cognitive impairment.
Methods
We recruited HIV-infected patients with cognitive impairment on stable antiretroviral therapy
in a randomized controlled pilot trial with a 48-week follow-up. An additional assessment
was held at 12 weeks. Participants received transdermal rivastigmine (9.5 mg daily), lithium
(400 mg twice daily, titrated progressively), or remained in a control group (no new medica-
tion). The primary efficacy endpoint was change in a global cognitive score (NPZ-7). Sec-
ondary endpoints included change in specific cognitive measures, domains, and functional
parameters. Safety covered the frequency of adverse events and changes in laboratory
results.
Results
Seventy-six subjects were screened, and 29 were finally enrolled. Better cognitive outcomes
were observed in all groups, although there were no significant differences between the
arms (mean NPZ-7 change [SD]): rivastigmine, 0.35 (0.14); lithium, 0.25 (0.40); control,
0.20 (0.44) (p = 0.78). The rivastigmine group showed the highest positive trend (mean
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NPZ-7 [SD], baseline vs week 48): rivastigmine, –0.47 (0.22) vs –0.11 (0.29), p = 0.06; lith-
ium, –0.50 (0.40) vs –0.26 (0.21), p = 0.22; control, –0.52 (0.34) vs –0.32 (0.52), p = 0.44.
The cognitive domains with the highest positive trends were information processing speed
at week 12 and executive function at week 48 (rivastigmine vs control): information process-
ing speed, 0.35 (0.64) vs –0.13 (0.25), p = 0.17, d = 0.96; and executive functioning, 0.73
(0.33) vs 0.03 (0.74), p = 0.09, d = 1.18. No relevant changes were observed regarding func-
tional outcomes. A total of 12 (41%) individuals dropped out of the study: 2 (20%) were due
to medication-related effects in the rivastigmine group and 4 (36%) in the lithium group. No
severe adverse events were reported.
Conclusions
The results from this small randomized trial indicate that transdermal rivastigmine did not
provide significant cognitive benefits in people with HAND on stable antiretroviral therapy,
even though positive trends were found in specific cognitive domains. Relevant tolerability
issues were not observed.
Introduction
Cognitive impairment has become a persistent complication in people with HIV infection,
despite the use of combination antiretroviral therapy (cART). Reports show a prevalence of
between 30% and 60% in people living with HIV during the recent cART era [1,2], and this
impairment appears to have a negative effect on quality of life [3], daily functioning [4], and
clinical outcomes (e.g., poor adherence to antiretroviral therapy and frequent virological fail-
ure) [5,6]. Adjuvant pharmacological therapies have been suggested for the management of
HIV-associated neurocognitive disorders (HAND), although most trials investigating them
have not proved clear benefits [7].
Rivastigmine is a cholinesterase inhibitor used to treat cognitive impairment, mainly in Alz-
heimer’s and Parkinson’s diseases [8]. Rivastigmine halts the action of the enzyme acetylcho-
linesterase, thus increasing levels of acetylcholine in the brain and enhancing the function of
neural cells, particularly those involved in attention and working memory processes [9]. This
drug also has beneficial non-cholinergic effects, including Aβ brain load reduction and neuro-
protective and anti-inflammatory effects in vivo and in vitro [10,11]. Both animal and human
studies have demonstrated that Aβ metabolism can be altered by HIV infection [12,13]. Oral
rivastigmine was tested in a randomized study of patients with HAND [14]. The authors
reported benefits in information processing speed, even though no significant improvement in
global cognitive functioning was established. Adverse effects were common (76%). Transder-
mal rivastigmine has a better tolerability profile than the oral formulation [8], although it has
not been assessed in the field of HIV infection. To date, the only compound that has proven
beneficial is lithium; however, its benefits appear to be variable, and the incidence of adverse
events, particularly hypothyroidism, diabetes insipidus, and lithium toxicity, is high [15,16].
We carried out a randomized controlled pilot trial with a 48-week follow-up, in which
patients received transdermal rivastigmine, lithium, or did not start new medication. We
assessed the safety and efficacy profile, considering change in cognitive functioning as the
main efficacy endpoint, and changes in specific measures, domains, and functional outcomes,
as secondary efficacy endpoints.
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Material and methods
Participants
The TRI-ANTiretroviral and Adjuvant ThErapies for HIV-associated cognitive impair-
ment (TRIANT-TE) trial was designed to investigate the safety and efficacy of transdermal
rivastigmine as treatment for cognitive impairment in HIV-infected patients. The study
was performed in the HIV Clinical Unit of the Germans Trias i Pujol University Hospital,
Badalona, Catalonia, Spain. Patients suspected of having HIV-associated cognitive im-
pairment were invited to participate in the study. The inclusion criteria were age 20 to 75
years, confirmed HIV infection, stable antiretroviral therapy (previous 6 months), con-
firmed undetectable plasma viral load, confirmed cognitive impairment (see Assessments
section), Catalan or Spanish as the native language, full understanding of the objectives
of the study, and written informed consent. The exclusion criteria were pregnancy, ther-
apy contraindicated with the study medications, and complications that prevented the
patient from starting the study drugs. Potential confounding comorbidities for cognitive
impairment were also considered exclusion criteria and were based on the proposal of the
Frascati group [17]. Those comorbidities included current or previous CNS-related dis-
ease, current or previous psychiatric disorder, current use of psychopharmacological med-
ication, use of illicit drugs, and coinfection with hepatitis C virus. The screening period
was from May 2011 to May 2013.
Study design
We developed a randomized controlled pilot trial, whose primary and secondary endpoints
were established for a 48-week follow-up. An additional assessment was performed at week 12.
Patients were randomized 1:1:1 to transdermal rivastigmine, lithium, or no new medication.
This assignment included stratification according to the antiretroviral CNS penetration-effec-
tiveness (CPE) score [18]. The score was balanced at baseline to avoid undesirable antiretrovi-
ral effects on CNS functioning. We calculated the mean score to be 8 in the population
attended in the center, and, therefore, we established 2 randomization tables depending on
whether the score was <8 or8. After randomization, participants were assigned to 1 of the
following study arms; the rivastigmine group (RG), which comprised patients who initiated
therapy with transdermal rivastigmine (Prometax1, Novartis, AG) and in which dosing was
started at 4.6 mg daily and increased to 9.5 mg daily at week 4; or the lithium group (LG), in
which patients initiated therapy with oral lithium (Plenur1, Faes Farma, SA) and in which
dosing was started at 400 mg twice daily before being titrated progressively to ensure plasma
drug concentrations of between 0.4 and 0.8 mEq/l. An appointment was made for 2 weeks and
4 weeks to monitor this dosing schedule. The control group (CG) comprised participants who
did not initiate a new treatment. Adherence to both antiretroviral therapy and study medica-
tion were monitored using the Self-Reported Adherence (SERAD) questionnaire [19]. Despite
the non-blinded character of the study, neuropsychologists were unaware of the specific partic-
ipation in each trial arm.
The study was managed by the Lluita contra la SIDA Foundation (http://www.flsida.org).
All study procedures were conducted in accordance with the 1964 Declaration of Helsinki
(fourth revision, 1996) and Good Clinical Practice guidelines. The study was approved by the
Research Ethics Committee of Germans Trias i Pujol University Hospital (project code: EO-07-
039). All patients gave their informed consent before enrolment. The trial is registered at Clini-
calTrials.gov (NCT01348282).
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Assessments
Patients underwent a comprehensive battery of neuropsychological tests that evaluated 7 cog-
nitive domains. The tests applied and the domains assessed were the following: the Letter-
Number and Digit tests of the Wechsler Adult Intelligence Scale—Version III (WAIS-III) [20],
for attention/working memory; the Trail Making Test—Part A (TMT-A) [21] and the Symbol
Digit Modalities Test (SDMT) [22], for information processing speed; the California Verbal
Learning Test—Version II (CVLT-II) [23], for verbal memory and learning; the Trail Making
Test—Part B (TMT-B) [21], the Stroop Test [24], the Wisconsin Card Sorting Test (WCST)
[25], and the Tower of London Test (TOL) [26], for executive functioning; the Controlled Oral
Word Association Test (COWAT) [27] and the Animals Test [28], for verbal fluency; and the
Grooved Pegboard Test (GPT) [29], for motor function. The Vocabulary Test of the WAIS-III
was used to monitor premorbid intelligence. Cognitive impairment was defined as performing
1 standard deviation below the normative mean in2 of the cognitive domains assessed, as
extensively reported in other studies in the field. Standardized z scores were used for all com-
parisons. They were obtained after adjusting the raw scores according to available normative
data in Catalan/Spanish and English, which covered principally age, gender, and educational
level [30–34]. The battery used for screening was the same as that used in the 12- and 48-week
study assessments. Cognitive complaints were recorded based on the European AIDS Clinical
Society guidelines [35]. HAND were determined based on the Frascati criteria [17]. Functional
outcomes were assessed by evaluating daily living, quality of life, and emotional status. Daily
living was evaluated using a version of the Instrumental Activities of Daily Living (IADL)
questionnaire in Catalan/Spanish, which covered 12 functional dimensions and included a
score measuring the total number of impaired areas [4]. Quality of life was recorded using a
reduced version of the Medical Outcomes Study HIV Health Survey (MOS-HIV) question-
naire [36], which covered 4 specific quality of life dimensions. Emotional status was evaluated
in terms of depression and anxiety symptoms, both of which were assessed using the Hospital
Anxiety and Depression Scale (HADS) [37]. Satisfaction was assessed based on 3 variables—
effort to take the new medication, ease of management of the new medication, and general sat-
isfaction with the treatment—and scored using 0–10–point Likert scales.
Statistical analyses
The data analyses were based mainly on prospective comparisons of primary and secondary
outcomes between baseline and 48-week study visits. They were applied with 2 groups (medi-
cation group vs control group) or all 3 groups (RG, LG, and CG) based on descriptive results
or the study endpoints. The primary efficacy endpoint was the change in neurocognitive func-
tioning from baseline to week 48 measured using the NPZ-7 score. The endpoint consisted of
a global composite measure comprising the mean of 7 neurocognitive measures, specifically
the letter-number total score (WAIS-III), TMT-A total time, long-term free recall (CVLT-II),
total A list (CVLT-II), TMT-B total time, COWAT total score, and GPT non-dominant hand
score. This score combination was selected because it has been shown to provide optimal sen-
sitivity and specificity for the detection of HIV-associated cognitive impairment [38]. The sec-
ondary endpoints comprised changes in specific cognitive measures and domains, daily living,
quality of life, and emotional variables, as well as satisfaction with the new treatment. The
safety analysis took account of changes in the frequency, type, and severity of adverse events.
Abnormal results in laboratory tests and changes over time in vital signs and symptoms were
also assessed. Additional comparisons included the assessment at week 12. Standardized z
scores were used for all comparisons with regard to cognitive endpoints. They were obtained
from local normative data when available, and were based principally on age, gender, and
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educational level. Daily living, quality of life, and emotional outcomes were treated as numeri-
cal outcomes from raw scores. Satisfaction levels were numerical and were compared between
medication arms. The statistical tests were applied according to the type of variable and
included the t test, chi-square test, and ANCOVA. All comparisons were univariate and
2-tailed. Statistical significance was set at p<0.05. Supplementary analyses with ANCOVA
were performed to study differences between the groups after adjustment for the variables that
were significantly unbalanced at baseline. Cohen’s effect size tests were performed to quantify
the magnitude of the differences found. Values were considered small when scores were less
than 0.40, medium when they ranged between 0.40 and 0.75, and large when they were over
0.75. All statistical analyses were performed using SPSS Statistics1, version 15 (SPSS Inc, Chi-
cago, Illinois, USA).
Results
Baseline characteristics
A total of 76 HIV-infected patients were screened. Twenty-five (32%) did not present cognitive
impairment, 19 (25%) did not meet the other study criteria, and 3 (4%) opted not to participate
(Fig 1). Thus, 29 individuals were randomized. By arm, 10 patients were allocated to the RG,
11 to the LG, and 8 to the CG.
Most patients were men (79%) and men who had sex with men (MSM) (55%), with a mean
(standard deviation) age of 44 (5) years. Mean time since HIV diagnosis was 12 (7) years, and
patients presented a mean CD4 count of 578 (217) cells/μL and a nadir CD4 count of 222
(121) cells/μL. Time since HIV diagnosis was not distributed equally between the groups (RG,
17 [7]; LG, 8 [4]; CG, 12 [7]; p = 0.02) (Table 1). This variable was included in the supplemen-
tary ANCOVAs.
No patients changed their cART regimen during the study, and there were no relevant
changes in viral load. Adherence to study medication at week 48 was90% for all patients in
the RG; 1 patient in the LG reported <90% adherence. The mean percentages were 100% (0%)
and 91% (19%), respectively. Median lithium drug levels were in the expected therapeutic
range at 12 weeks (0.5 [0.4–0.6] mEq/l) and at 48 weeks (0.5 [0.3–0.8] mEq/l).
Efficacy outcomes
At week 12, no differences were found in the primary study endpoint. All groups showed bet-
ter cognitive outcomes, although none reached statistical significance (mean [SD] NPZ-7
change): RG, 0.27 (0.38); LG, 0.10 (0.21); CG, 0.15 (0.53); p = 0.66. The most pronounced
trend towards improvement was observed in the RG (mean [SD] NPZ-7, baseline vs wk12):
RG, –0.38 (0.28) vs –0.11 (0.30), p = 0.10; LG, –0.26 (0.28) vs –0.16 (0.23), p = 0.43; CG, –0.52
(0.34) vs –0.39 (0.57), p = 0.63. The WAIS-III digit span backward score (attention/working
memory) revealed significant differences, with a large effect size, showing better functioning in
the RG than in the CG (RG vs CG): 0.10 (0.26) vs –0.48 (0.37), p<0.01, d = 1.84. The domain
that improved most was information processing speed in the RG (RG vs CG): 0.35 (0.64) vs –
0.13 (0.25), p = 0.17, d = 0.96. With regard to daily living and quality of life outcomes, no dif-
ferences were observed in any areas. Symptoms of depression and anxiety were less frequent in
both the RG and the LG, particularly in the LG, albeit without reaching statistical significance:
RG, –1.57 (3.45); LG, –3.37 (3.11); CG, –0.20 (3.27); p = 0.24; RG, –1.00 (2.70); LG, –1.75
(4.74); CG, 2.40 (4.82); p = 0.22, respectively.
At week 48, cognitive outcomes were still better in all groups, although significant differ-
ences were still not found for the primary endpoint (mean [SD] NPZ-7 change): RG, 0.35
(0.14); LG, 0.25 (0.40); CG, 0.20 (0.44); p = 0.78 (Table 2). The most pronounced trend
Transdermal rivastigmine in HIV infection
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towards benefits was observed for the RG (mean [SD] NPZ-7, baseline vs week 48): RG, –0.47
(0.22) vs –0.11 (0.29), p = 0.06; LG, –0.50 (0.40) vs –0.26 (0.21), p = 0.22; CG, –0.52 (0.34) vs –
0.32 (0.52), p = 0.44. The adjusted analyses with the supplementary ANCOVA, which were
corrected for time since HIV diagnosis, confirmed the unadjusted results. The TOL total
moves measure (executive functioning) revealed a trend towards benefits in the RG and a sig-
nificantly better score in the LG when both were compared with the CG, with large effect sizes
in both cases: RG vs CG, 0.70 (0.73) vs –0.61 (1.28), p = 0.07, d = 1.22; LG vs CG, 1.05 (0.81) vs
–0.61 (1.28), p = 0.02, d = 1.55. In terms of domains, executive functioning revealed a slightly
clearer trend towards improvement in the RG, with a large effect size: RG vs CG: 0.73 (0.33) vs
0.03 (0.74), p = 0.09, d = 1.18 (Fig 2). No relevant associations were found when other potential
explicative variables (e.g., education level, age, or time since HIV diagnosis) were included in
the analyses. Regarding daily living, quality of life, and emotional status, significant differences
were only found for a single measure of daily activities (cooking), with a better score in the RG
than in the CG: RG vs CG: –0.40 (0.54) vs 0.33 (0.81), p = 0.04, d = –1.39 (Table 3). Satisfaction
levels did not differ between the medication groups and were fairly positive overall (RG vs
LG): effort, 1.6 (3.04) vs 3.33 (3.88), p = 0.43, d = –0.49; ease, 6.8 (3.27) vs 7.83 (1.72), p = 0.51,
d = –0.41; satisfaction, 7 (1) vs 7 (2.52), p = 1.00, d = 0.00.
Fig 1. Flow diagram of trial participation.
https://doi.org/10.1371/journal.pone.0182547.g001
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Safety outcomes
A total of 12 (41%) participants dropped out of the study. At week 12, 3 (30%) had discon-
tinued in the RG, 2 (18%) in the LG, and 2 (25%) in the CG. The reasons for discontinua-
tion in the RG were low-grade gastrointestinal effects and low-grade fatigue considered
related to the study medication in one patient, epistaxis that was considered unrelated to
the study medication in another patient, and personal reasons in the third patient. In the
LG, one patient discontinued owing to decreased levels of the hormone T4, which indicated
low-grade hypothyroidism (0.74 [normal range, 0.82–1.77]), and another developed acute
hepatitis B infection, which was considered unrelated to lithium. In the CG, one patient
Table 1. Baseline characteristics of study participants.
Rivastigmine
(n = 10)
Lithium
(n = 11)
Control
(n = 8) p Value
Age, y, mean (SD) 45 (7) 43 (5) 45 (3) 0.592
Male, n (%) 7 (70) 9 (81) 7 (87) 0.640
Years of education, mean (SD) 11 (4) 13 (5) 12 (4) 0.497
Route of transmission, n (%) 0.255
Injecting drug user 2 (20) 2 (18) 2 (25)
Heterosexual 4 (40) 2 (18) 0 (0)
MSM 4 (40) 6 (55) 6 (75)
Other 0 (0) 1 (9) 0 (0)
Time since HIV diagnosis, y, mean (SD) 17 (7) 8 (4) 12 (7) 0.020*
Months on current ARV regimen, mean (SD) 34 (30) 31 (24) 36 (22) 0.918
ARV regimen, n (%) 0.661
NNRTI-based 2 (20) 5 (45) 4 (50)
PI-based 6 (60) 5 (45) 3 (38)
II-based 2 (20) 1 (10) 1 (12)
CPE score, mean (SD) a 7.4 (1.5) 7.0 (2.6) 7.8 (1.1) 0.633
CD4 cell count, mean (SD) 591 (211) 649 (206) 463 (218) 0.180
Nadir CD4 cell count, mean (SD) 180 (126) 280 (100) 194 (123) 0.124
Undetectable plasma viral load, n (%) b 10 (100) 11 (100) 8 (100) -
Highest plasma viral load, mean (SD) 228,525 (305,909) 379,200 (481,250) 100,666 (106,281) 0.298
Depression symptoms, mean (SD) c 8 (5) 6 (4) 7 (4) 0.789
Anxiety symptoms, mean (SD) c 9 (4) 10 (3) 8 (4) 0.765
Cognitive complaints, n (%) d 6 (60) 10 (91) 7 (87) 0.184
NPZ-7, mean (SD) –0.56 (0.59) –0.29 (0.95) –0.58 (0.35) 0.584
HAND, n (%) e 0.196
ANI 2 (20) 0 (0) 1 (12)
MND 8 (80) 11 (100) 7 (88)
HAD 0 (0) 0 (0) 0 (0)
Abbreviations: ANI, asymptomatic neurocognitive impairment; ARV, antiretroviral; CPE, central nervous system penetration-effectiveness; HAD, HIV-
associated dementia; HAND, HIV-associated neurocognitive disorder; II, integrase inhibitor; MND, mild neurocognitive disorder; MSM, men who had sex
with men; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
a Based on the proposal by Letendre et al (2010).18
b Detection limit of40 copies/mL.
c Assessed using the Hospital Anxiety-Depression Scale (HADS).39
d Based on the proposal by the European AIDS Clinical Society (EACS).36
e According to the Frascati criteria (2007).17
* p<0.05.
https://doi.org/10.1371/journal.pone.0182547.t001
Transdermal rivastigmine in HIV infection
PLOS ONE | https://doi.org/10.1371/journal.pone.0182547 August 30, 2017 7 / 14
was excluded because of uncompleted assessments, and another developed emotional dis-
turbances. From week 12 to week 48, 2 (20%) patients dropped out in the RG, and 3 (27%)
in the LG. In the RG, one withdrew because of patch-related skin irritation, and another
developed depression linked to personal problems. In the LG, one patient developed hypo-
thyroidism, another tremors and rash, and the third headache and asthenia. In all 3 cases,
the symptoms were considered adverse events associated with lithium. In total, therefore, 2
(20%) participants dropped out because of adverse events in the RG, and 4 (36%) in the LG.
Blood tests revealed no significant changes in complete blood count, biochemistry, or
immunology, and no other clinical abnormalities were recorded during follow-up.
Discussion
The results from this small randomized trial show that transdermal rivastigmine was generally
well tolerated by HIV-infected patients on stable cART, although no significant improvements
Table 2. Change in cognitive measures at week 48.
Rivastigmine
(n = 5)
Lithium
(n = 6)
Control
(n = 6)
p Value a; b d Size a; b
Attention/working memory
Digit span forward (WAIS-III) 0.28 (0.38) 0.11 (0.68) 0.58 (0.68) 0.404; 0.267 –0.53; –0.69
Digit span backward (WAIS-III) –0.32 (0.43) –0.01 (0.69) –0.36 (0.80) 0.910; 0.437 0.06; 0.47
Letters-numbers (WAIS-III) –0.08 (0.65) 0.01 (0.91) 0.21 (0.38) 0.372; 0.631 –0.56; –0.29
Information processing speed
Total time (TMT-A) 0.64 (1.14) 0.90 (1.56) 0.61 (0.72) 0.968; 0.695 0.03; 0.24
Written score (SDMT) –0.06 (0.44) 0.25 (0.24) 0.28 (0.56) 0.296; 0.896 –0.67; –0.07
Verbal memory
Long-term free recall (CVLT-II) 0.40 (0.89) 0.33 (0.60) –0.08 (1.06) 0.443; 0.425 0.49; 0.48
Learning
Total A list (CVLT-II) 0.60 (0.40) 0.61 (0.88) 0.26 (1.33) 0.607; 0.604 0.33; 0.31
Executive functioning
Total time (TMT-B) 0.60 (0.89) –0.30 (1.80) 0.33 (1.52) 0.739; 0.526 0.21; –0,38
Interference score (Stroop test) 0.72 (0.52) 0.38 (0.72) –0.10 (0.84) 0.101; 0.331 1.15; 0.61
Total moves (TOL) 0.70 (0.73) 1.05 (0.81) –0.61 (1.28) 0.073; 0.022 1.22; 1.55
Percentage errors (WCST) 0.90 (1.11) 0.35 (0.69) –0.02 (1.28) 0.260; 0.556 0.76; 0.36
Verbal fluency
Total score (COWAT) 0.48 (0.55) 0.23 (0.88) 0.15 (0.42) 0.290; 0.839 0.68; 0.11
Total score (Animals test) 0.06 (0.90) –0.36 (0.77) –0.05 (0.62) 0.817; 0.455 0.14; –0.44
Motor function
Dominant hand time (GPT) 0.38 (0.93) –0.08 (0.71) –0.21 (0.93) 0.778; 0.545 0.63; 0.15
Non-dominant hand time (GPT) 0.56 (0.92) –0.16 (0.39) –0.11 (0.71) 0.202; 0.883 0.82; –0.09
Global
NPZ-7 0.35 (0.14) 0.25 (0.40) 0.20 (0.44) 0.484; 0.849 0.38; 0.12
Values are expressed as mean (standard deviation) except when indicated otherwise.
Higher change scores represent improvement.
Abbreviations: COWAT, Controlled Oral Word Association Test; CVLT-II, California Verbal Learning Test—Version II; GDS, global deficit score; GPT,
Grooved Pegboard Test; SDMT, Symbol Digit Modalities Test; TMT-A, Trail Making Test—Part A; TMT-B, Trail Making Test—Part B; WAIS-III, Wechsler
Adult Intelligence Scale—Version III; WCST, Wisconsin Card Sorting Test; TOL, Tower of London.
a Comparison between rivastigmine group and control group.
b Comparison between lithium group and control group.
https://doi.org/10.1371/journal.pone.0182547.t002
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in cognitive functioning or other relevant functional parameters were recorded. The study
sample comprised mostly highly educated middle-aged MSM who were virologically sup-
pressed, with no potential confounding comorbidities for cognitive impairment.
Fig 2. Changes in NPZ-7 and in information processing speed and executive functioning domains. (a) Mean change in NPZ-7. (b) Mean change
in information processing speed. (c) Mean change in executive functioning. Values are expressed as z-score means, bars as standard errors. P values
and d sizes are provided for rivastigmine vs control group comparisons. Abbreviations: CG, control group; EF, executive functioning; IPS, information
processing speed; LG, lithium group; RG, rivastigmine group.
https://doi.org/10.1371/journal.pone.0182547.g002
Table 3. Change in daily living, quality of life, and emotional variables.
Rivastigmine
(n = 5)
Lithium
(n = 6)
Control
(n = 6)
p Value a; b d Size a; b
Daily living
Finances 0.20 (0.83) 0.16 (0.40) 0 (0) 0.568; 0.340 0.36; 0.57
Doing the shopping 0 (0) 0.33 (0.81) 0 (0.63) 1; 0.447 0; 0.45
Cooking –0.40 (0.54) 0.33 (0.81) 0.33 (0.51) 0.048; 1 –1.39; 0
Social activities 0 (0.70) 0 (0.89) –0.50 (0.54) 0.218; 0.270 0.81; 0.68
Reading/watching TV 0 (0.70) 0 (0.63) 0.16 (0.40) 0.635; 0.599 –0.29; –0.30
Driving –0.20 (0.44) 0.16 (0.40) 0 (0) 0.296; 0.340 –0.68; 0.57
Using the telephone 0 (0) 0.16 (0.75) 0.16 (0.75) 0.635; 1 –0.29; 0
Home repairs 0.20 (0.44) –0.50 (0.83) 0 (0) 0.296; 0.173 0.68; –0.85
Going shopping 0.20 (0.44) 0.33 (0.51) 0 (0.63) 0.568; 0.340 0.36; 0.58
Washing clothes –0.20 (0.44) 0.16 (0.40) 0.16 (0.40) 0.188; 1 –0.86; 0
Medication management 0 (0) 0 (0) 0 (0.63) 1; 1 0; 0
Work –0.20 (0.83) 0 (0.63) 0.50 (0.83) 0.200; 0.270 –0.84; –0.68
Total impaired areas –0.60 (3.71) 1 (4.64) 0.66 (3.72) 0.587; 0.893 –0.34; 0.08
Quality of life
Physical dimension –0.20 (0.44) –0.50 (0.83) 0.16 (0.75) 0.365; 0.177 –0.57; –0.83
Mental dimension 0 (0.70) 0.16 (0.98) 0 (0.63) 1; 0.734 0; 0.19
Social dimension 0 (0.70) 0 (1.26) –0.16 (0.75) 0.715; 0.787 0.22; 0.15
Global quality of life –0.20 (0.44) 0 (1.26) 0 (0) 0.296; 1 –0.68; 0
Emotional status
Depression symptoms –1.20 (4.14) –0.20 (0.83) –1.20 (3.83) 1; 0.584 0; 0.36
Anxiety symptoms –1.60 (2.88) 0.60 (5.31) 1.20 (5.54) 0.345; 0.865 –0.61; –0.11
Values are expressed as mean (standard deviation) except when indicated otherwise.
For daily functioning, lower change scores represent improvement.
For quality of life, higher change scores represent improvement.
For emotional status, lower change scores represent improvement.
a Comparison between rivastigmine group and control group.
b Comparison between lithium group and control group.
https://doi.org/10.1371/journal.pone.0182547.t003
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Trials testing adjuvant therapies for HIV-related neurocognitive complications have been
carried out for years. Since the advent of cART, 12 compounds in a total of 18 trials have been
investigated.7 The therapies included mainly lithium, memantine, minocycline, selegiline, and
valproic acid. The studies found no relevant benefits regarding cognitive functioning, except
for mild improvements with lithium. Most of the studies prioritized safety and tolerability
over efficacy. The studies also revealed discrepancies with regard to the populations studied
and the definition of cognitive change. We designed a study to investigate clear efficacy-based
clinical endpoints that examined a wide range of cognitive measures and domains. Functional
parameters, specifically assessment of daily living, quality of life, and emotional status, have
received little attention in previous trials in the field. We analyzed both functional parameters
and satisfaction outcomes. Nonetheless, our findings did not reveal relevant differences in any
of these dimensions, although a slight trend towards improvement was observed in the rivas-
tigmine arm. The efficacy of rivastigmine has been demonstrated in Alzheimer’s and Parkin-
son’s diseases, neurodegenerative processes in which dementia, rather than mild cognitive
impairment, is more common [39,40]. Our study sample, while mostly comprising people
with mild neurocognitive disorder (MND), did not incorporate cases of HIV-associated
dementia; therefore, this cholinesterase may not have been sufficiently potent to achieve an
effect on subtle cognitive deficits.
Simioni et al are the only other authors to have previously investigated the effects of rivastig-
mine in patients with HIV-associated cognitive impairment [14]. After a 20-week study, they
concluded that rivastigmine enhanced neurocognitive performance, although this was observed
exclusively in 1 measure of information processing speed, out of a total of 12 cognitive measures
covering 4 cognitive domains. Our study period was 48 weeks, with an assessment at week 12,
which was to some extent comparable to their 20-week assessment. Interestingly, we found
information processing speed to be the domain that showed a clearer trend towards improve-
ment. In addition, we detected a significant difference in a measure of attention/working mem-
ory (WAIS-III digit span backward score), a domain that is known to overlap with information
processing speed depending on the tests used [41]. Both effects, however, were lost at week 48,
when the only domain with a significantly better score was executive functioning (TOL total
moves measure), for which Simioni et al found a tendency towards improvement at 20 weeks.
Hence, findings from both trials appear to be consistent, despite the absence of statistically sig-
nificant differences. We also observed an improvement in cognitive outcomes in the 3 study
arms, thus indicating that the results could be affected by a practice effect linked to neuropsy-
chological testing. Nevertheless, we incorporated a control group, and our endpoints were pre-
dominantly based on the comparison between the medication arms and the control group,
rather than a longitudinal approach.
Transdermal rivastigmine has proven to be better tolerated than the oral formulation [8].
Indeed, we found that discontinuation due to side effects was less frequent than Simioni et al
(10% vs 23%, respectively), although we assessed this variable 8 weeks earlier. Thirty-six weeks
later (at 48 weeks), the rate of discontinuation was similar to that described by Simioni et al,
although in their case the assessment was at week 20 (20% vs 23%).
Because most efficacy results in the field were reported from week 10 to 24, we decided to
extend our trial to 48 weeks and add an assessment at week 12. We were therefore able to report
results that could be compared with previous findings and to better monitor the dynamics of
the changes observed. The inclusion of the lithium arm is also a unique characteristic that
enabled us to perform 2- and 3-arm comparisons. Furthermore, we used effect size tests to pro-
vide unbiased additional information rather than traditional p values because of the reduced
group sizes. The results supported the trends observed, with some large and very large effects
(e.g., in executive functioning). Our trial also benefited from stratification based on the CPE
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score, which has rarely been monitored in previous studies exploring adjuvant therapies, despite
its relevance in the setting of HIV infection.
Our study is subject to a series of limitations. First, the sample was small, with few patients
in each group; consequently, results that might have represented more significant changes
may have gone undetected. Additionally, despite the randomized controlled design, represen-
tation for some baseline variables was uneven. The adjusted analyses subsequently confirmed
previous results, but this was not an ideal approach, especially given the original design of the
study. Another limitation was the non-blinded character of the trial. Although this approach
was intrinsic to the type of investigation—rivastigmine was administered with a transdermal
patch and the lithium dosage was adjusted according to drug blood levels—it decreased the
methodological power of the design. The trial was also limited by the absence of an extra study
assessment between the 12- and the 48-week visits. This could have provided valuable data on
the dynamics of study outcomes during follow-up. Furthermore, study efficacy outcomes were
established based exclusively on neurocognitive functioning, and neuroimaging parameters or
potentially representative CNS biomarkers were not taken into account. Both types of markers
are essential when studying therapeutic strategies for HAND.
In summary, the results of this randomized controlled trial suggest that transdermal rivas-
tigmine does not provide a significant cognitive benefit for HIV-infected persons on cART
after a 48-week follow-up, despite the tolerability profile was better than that of the oral formu-
lation. Given the fact that ours was a pilot study, the small sample size, and, particularly, the
dropout rate, a larger controlled trial should be conducted to contrast our results. In order to
ensure appropriate testing of the actual effects of rivastigmine in people with HAND, new tri-
als should include additional markers of CNS functioning and, probably, individuals with
more marked cognitive impairment.
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